Home > Risk of adverse outcomes during gabapentinoid therapy and factors associated with increased risk in UK primary care using the clinical practice research datalink: a cohort study.

Muller, Sara and Bailey, James and Bajpai, Ram and Helliwell, Toby and Harrisson, Sarah A and Whittle, Rebecca and Mallen, Christian D and Ashworth, Julie (2024) Risk of adverse outcomes during gabapentinoid therapy and factors associated with increased risk in UK primary care using the clinical practice research datalink: a cohort study. Pain, Early online, doi: 10.1097/j.pain.0000000000003239.

External website: https://journals.lww.com/pain/fulltext/9900/risk_o...


Growing evidence from pharmacovigilance data and postmortem toxicology reports highlights the misuse potential of gabapentinoids. This study aimed to investigate the risk of serious adverse outcomes (drug misuse, overdose, major trauma), and their risk factors, in primary care patients who are prescribed gabapentinoids. Using the UK Clinical Practice Research Datalink, a matched cohort study calculated adverse event rates separately for gabapentinoid-exposed and unexposed cohorts. In the exposed cohort, event rates for exposure to a range of potential risk factors were calculated. Event rates were compared using Cox proportional hazards models, adjusted for age, sex, deprivation, previous mental health diagnosis, and coprescribing with potentially interacting medicines. Substance misuse (gabapentin adjusted hazard ratio [95% CI]: 2.40 [2.25-2.55]), overdose (2.99 [2.56-3.49]), and major trauma (0-2.5 years: 1.35 [1.28-1.42]; 2.5 to 10 years: 1.73 [1.56-1.95]) were more common among patients prescribed gabapentinoids than matched individuals who were not. The association with overdose was stronger for pregabalin than gabapentin. All adverse outcomes were significantly associated with smoking, history of substance misuse, overdose, or a mental health condition and prescription of opioids, benzodiazepines, antidepressants, and Z-drug hypnotics (eg, gabapentin hazard ratios for association of concurrent opioid use: misuse 1.49 [1.47-1.51]; overdose 1.87 [1.78-1.96]; major trauma 1.28 [1.26-1.30]). Our findings highlight the importance of careful patient selection when prescribing gabapentinoids and the need to educate prescribers about the risks of these drugs, particularly in combination with other central nervous system depressants.

Summary:

  • Keele researchers have found a link between patients prescribed gabapentinoids and a greater risk of ‘adverse events’ such as drug misuse, overdose, and major trauma such as a bone fracture or head injury. 
  • The researchers looked at anonymised GP records to compare rates of adverse events in patients who were prescribed gabapentin or pregabalin therapeutically by their doctor, with those who were not. 
  • Adverse events in patients prescribed gabapentinoids were more likely if they were a smoker, had a history of substance misuse, overdose, or a mental health condition, and if they were also prescribed other drugs that affect the central nervous system.

Repository Staff Only: item control page